KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Cost of Revenue: 2018-2024

Historic Cost of Revenue for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $60.2 million.

  • Castle Biosciences' Cost of Revenue rose 19.83% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.9 million, marking a year-over-year increase of 22.06%. This contributed to the annual value of $60.2 million for FY2024, which is 33.84% up from last year.
  • According to the latest figures from FY2024, Castle Biosciences' Cost of Revenue is $60.2 million, which was up 33.84% from $45.0 million recorded in FY2023.
  • In the past 5 years, Castle Biosciences' Cost of Revenue registered a high of $60.2 million during FY2024, and its lowest value of $9.7 million during FY2020.
  • In the last 3 years, Castle Biosciences' Cost of Revenue had a median value of $45.0 million in 2023 and averaged $45.7 million.
  • Data for Castle Biosciences' Cost of Revenue shows a peak YoY soared of 102.31% (in 2022) over the last 5 years.
  • Over the past 5 years, Castle Biosciences' Cost of Revenue (Yearly) stood at $9.7 million in 2020, then surged by 63.37% to $15.8 million in 2021, then surged by 102.31% to $32.0 million in 2022, then skyrocketed by 40.53% to $45.0 million in 2023, then spiked by 33.84% to $60.2 million in 2024.